Background: Pregnant women with inflammatory bowel disease frequently experience suboptimal perinatal outcomes. One Taiwanese study conducted from 2001 to 2003 revealed higher risks of preterm birth and low birth weight in infants born to mothers with ulcerative colitis. With the advancement in disease management, we aim to investigate the pregnancy and perinatal outcomes of Taiwanese mothers with inflammatory bowel disease between 2004 and 2018.
Methods: We integrated data from Taiwan's Maternal and Child Health Database, Birth Reporting Database, National Health Insurance Database, and Catastrophic Illness Registry from 2004 to 2018. Mothers with inflammatory bowel disease were identified using International Classification of Diseases codes and the Catastrophic Illness Registry and matched 1:10 with healthy pregnant women based on the year of childbirth and maternal age. Statistical analyses involved chi-squared tests and conditional logistic regression models.
Results: A total of 3,059,647 births were recorded, of which 146 were born to mothers with IBD (126 to those with ulcerative colitis and 20 to those with Crohn's disease). We observed no significant differences in stillbirths, preterm births, cesarean deliveries, low birth weights, small- or large-for-gestational-age newborns, or Apgar scores between the mothers with inflammatory bowel disease and the controls. Hypertensive disorders of pregnancy were less prevalent in the inflammatory bowel disease group (4.1% vs 13.6%; P = 0.001). Subgroup analysis revealed consistent outcomes in both ulcerative colitis and Crohn's disease, across socioeconomic status, and disease duration.
Conclusions: Pregnancy and perinatal outcomes are comparable in Taiwanese women with inflammatory bowel disease and matched healthy counterparts. While no statistically significant differences were observed, the limited statistical power for certain outcomes warrants cautious interpretation. These findings highlight the need for further investigation in larger cohorts or pooled datasets to explore small but potentially clinically meaningful differences.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jfma.2025.02.034 | DOI Listing |
J Microbiol Immunol Infect
March 2025
Chang Gung Microbiota Therapy Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Electronic address:
Background: Clostridium innocuum is a vancomycin-resistant pathobiome associated with poor clinical outcomes in inflammatory bowel disease (IBD). In ulcerative colitis (UC), it correlates with reduced remission rates, while in Crohn's disease (CD), it is linked to creeping fat formation and intestinal strictures. Notably, some patients experience refractory or recurrent C.
View Article and Find Full Text PDFDig Liver Dis
March 2025
Department of Pathophysiology and Organ Transplantation, University of Milan, Milan, Italy; Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Electronic address:
Mucosal healing is the mainstream goal of modern treat-to-target strategy as it is associated with a significantly more favorable disease course in IBD patients with either ulcerative colitis or Crohn's disease. Recent advances in endoscopic imaging technologies have overcome the traditional concept of mucosal healing assessed with conventional white light imaging, allowing for multiple levels of endoscopic healing up to the boundaries of molecular and functional evaluation. In this review, we focused on conventional and emerging strategies to assess endoscopic healing in ulcerative colitis and ileocolonic Crohn's disease, examining their pros and cons in real life practice.
View Article and Find Full Text PDFGut
March 2025
Department of Gastroenterology, Shanghai Tenth People's Hospital, Shanghai, China
Background: GPR171 suppresses T cell immune responses involved in antitumour immunity, while its role in inflammatory bowel disease (IBD) pathogenesis remains unclear.
Objective: We aimed to investigate the role of GPR171 in modulating CD4 T cell effector functions in IBD and evaluate its therapeutic potential.
Design: We analysed GPR171 expression in colon biopsies and peripheral blood samples from patients with IBD and assessed the impact of GPR171 on CD4 T cell differentiation through administration of its endogenous ligand (BigLEN).
Gastroenterology
March 2025
APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.
Inflammatory bowel disease (IBD) is marked by significant clinical heterogeneity, posing challenges for accurate diagnosis and personalized treatment strategies. Conventional approaches, such as endoscopy and histology, often fail to adequately and accurately predict medium and long-term outcomes, leading to suboptimal patient management. Artificial intelligence (AI) is emerging as a transformative force enabling standardized, accurate, and timely disease assessment and outcome prediction, including therapeutic response.
View Article and Find Full Text PDFInflamm Bowel Dis
March 2025
Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!